Ph.D., Senior Director, Product Sciences, Genomic Health Inc.
Kim recently led the development and analytic validation of Oncotype SEQ® Liquid Select, the first liquid and NGS-based product offering from Genomic Health. She also led the transition of Liquid Select from Development to the CLIA certified Clinical Laboratory, where it is currently being used to aid in treatment decision making for patients with late stage NSCLC. Kim also leads the Product Sciences group, a talented team of development scientists involved in new product development. Kim has been with Genomic Health for over 16 years, during which time she was involved in the development and validation of Oncotype DX® gene expression tests for Breast Cancer (Breast Recurrence Score), Colon Cancer (Colon Recurrence Score) and Prostate Cancer (Genomic Prostate Score). Prior to joining Genomic Health, Kim studied the role of mitochondrial DNA dimers in cancer at Stanford University. Kim received her B.Sc. in Genetics and Ph.D. in Mitochondrial Genetics at the University of Newcastle Upon Tyne, England.
Presentation Title and Company Description
Clinical Dx Showcase: Challenges of Analytic Validation for NGS Liquid Biopsy Assays
Genomic Health, Inc. is the world’s leading provider of genomic-based diagnostic tests that help optimize cancer care. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey.